Skip to main content
padlock icon - secure page this page is secure

Treatment and dose prioritization in early phase platform trials of targeted cancer therapies

Buy Article:

$52.00 + tax (Refund Policy)

With the advances in the discovery of molecular targets, there is increasing interest in evaluating targeted therapies for disease subtypes characterized by certain biomarkers. Patients with a certain biomarker could potentially benefit from different experimental drugs, and, therefore, evaluating the relative efficacy of these drugs is an important objective. We consider the design of an early phase platform trial where multiple therapies are evaluated in patients with different biomarkers, with the objective of identifing the best drug at an efficacious and safe dose for a given disease subtype. We use the continual reassessment method to estimate the maximum tolerated dose of a drug and adopt hierarchical Bayesian modelling to estimate the efficacy of a drug administered at multiple doses. Using the continual reassessment method and hierarchical Bayesian modelling as the basis of inference, we propose various algorithms that prescribe the drug–dose for the patients using adaptive randomization. We demonstrate that adaptive randomization puts more patients at the right drug and dose on average than does balanced randomization, with slightly larger variability in distribution, and has no effect on the accuracy of drug–dose selection. Moreover the simulations show advantages of hierarchical Bayesian modelling over the beta–binomial model in scenarios with relatively flat or partially flat dose–efficacy relationships.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Adaptive randomization; Bayesian design; Continual reassessment method; Hierarchical Bayesian model; Phase I trials; Targeted cancer therapy

Document Type: Research Article

Publication date: February 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more